Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

8bb3effb4809e3.bclWiNKcQ5nB2pbVG0gDl_03hKBvaEMJi_hA_krIEfg.CY0gyqbDOfbzj_CmXnhV559Q1sFfDxJBvrEIqw2rXb4GuRHH6_cFz5ji5Q~305dcffefc80452077bfcd1a5003c28c
07-01 Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating MT
05-07 RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating MT
03-05 Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating MT
11-06 RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk MT
25-10-15 Cooking oil, hot markets Zonebourse
25-08-14 Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating MT
25-06-17 RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target MT
25-05-16 Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating MT
25-01-07 Citigroup Initiates EyePoint Pharmaceuticals at Buy With $33 Price Target MT
24-10-16 Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target MT
24-08-28 Jefferies Initiates EyePoint Pharmaceuticals at Buy MT
24-06-04 JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating MT
24-05-08 Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating MT
24-05-07 Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating MT
24-05-07 Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating MT
24-02-15 Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating MT
24-01-22 JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target MT
23-12-11 Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target MT
23-12-07 Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating MT
23-11-02 HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating MT
23-11-02 Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20 MT
23-06-14 JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target MT
23-05-19 HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating MT
23-05-19 Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating MT
22-11-11 Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+5.85%
+1.75%
+7.06%
+8.62%
+0.2%
+26.2%
-2.31%
-1.06%
+20.47%
Average +7.42%
Weighted average by Cap. +6.38%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.28USD
Average target price
40.54USD
Spread / Average Target
+183.88%
High Price Target
68.00USD
Spread / Highest target
+376.19%
Low Price Target
20.00USD
Spread / Lowest Target
+40.06%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Chardan Research
RBC Capital Markets
Mizuho Securities
Citigroup
Scotiabank
JPMorgan Chase
Baird
Capital One Securities
HC Wainwright
JonesTrading Institutional Services
Guggenheim
Cowen
Cantor Fitzgerald
B. Riley
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.28USD
Average target price
40.54USD
Spread / Average Target
+183.88%

Quarterly revenue - Rate of surprise